Enhancement or prolongation of GLP-1 activity as a strategy for treatment of type 2 diabetes

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 2, 2004, Pages 207-212

  Ahrén, Bo ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIDIABETIC AGENT; CJC 1131; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENTEROSTATIN; EXENDIN 4; GASTRIN RELEASING PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; GROWTH HORMONE RELEASING FACTOR; HEMOGLOBIN A1C; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INSULIN; LIRAGLUTIDE; LONG ACTING DRUG; NEUROPEPTIDE Y; NVPDPP 728; ORAL ANTIDIABETIC AGENT; PEPTIDE HISTIDINE METHIONINE; PEPTIDE YY; PLACEBO; SHORT ACTING DRUG; SOMATOMEDIN; SUBSTANCE P; SULFONYLUREA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

ARTICLE; DIET THERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; EXERCISE; GENE INACTIVATION; GENE TARGETING; GLUCOSE HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 13344281982     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.08.001     Document Type: Review

References (21)

1. D. Porte Jr. S.E. Kahn The key role of islet dysfunction in type II diabetes mellitus Clin. Invest. Med. 18 1995 247-254
2. B. Ahrén Glucagon-like peptide 1 (GLP-1) - a gut hormone of potential interest in the treatment of diabetes BioEssays 20 1998 642-651
3. M.D. Turton et al. A role for glucagon-like peptide-1 in the central regulation of feeding Nature 379 1996 69-72
4. D.J. Drucker Glucagon-like peptides: Regulators of cell proliferation, differentiation and apoptosis Mol. Endocrinol. 17 2003 161-171
5. M. Gutniak et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus N. Engl. J. Med. 326 1992 1316-1322
6. M. Zander et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study Lancet 359 2002 824-830
7. B. Ahrén Gut peptides and type 2 diabetes mellitus treatment Curr. Diabetes Rep. 3 2003 365-372
8. R. Ritzel et al. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1(17-36amide) after subcutaneous injection in healthy volunteers: Dose-response-relationships Diabetologia 38 1995 720-725
9. C.F. Deacon et al. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo J. Clin. Endocrinol. Metab. 80 1995 952-957
10. R. Mentlein Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides Regul. Pept. 85 1999 9-24
11. H. Agersø et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men Diabetologia 45 2002 195-202
12. B. Rolin et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice Am. J. Physiol. 283 2002 E745-E752
13. C.B. Juhl et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes Diabetes 51 2002 424-429
14. A.A. Young et al. Glucose-lowering and insulin sensitising actions of exendin-4; strudies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta) Diabetes 48 1998 1026-1034
15. M.S. Fineman et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes Diabetes Care 26 2003 2370-2377
16. O.G. Kolterman et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes J. Clin. Endocrinol. Metab. 88 2003 3082-3089
17. J.G. Kim et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate Diabetes 52 2003 751-759
18. J.J. Holst C.F. Deacon Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes Diabetes 47 1998 1663-1670
19. D. Marguet et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 Proc. Natl. Acad. Sci. USA 97 2000 6874-6879
20. B. Ahrén et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4 week study period in type 2 diabetes Diabetes Care 25 2002 869-875
21. B. Ahrén et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes J. Clin. Endocrinol. Metab. 89 2004 2078-2084